The Burden of Nonsterile to Sterile Compounding of Alum
Publisher: Edge Pharma
Access this content
Your content has been opened.
The Burden of Nonsterile to Sterile Compounding of Alum has been emailed to . Entered the wrong email?
Don't see the content in your inbox?
Make sure to check your spam and other messages folders.
Can't get to your email right now?
To complete your registration and access this content, enter the sign-in code sent to your email.
Please enter a valid verification code.
Code sent to:
Register to access this content
By accessing content on the Pharmaceutical Manufacturing Resource Directory you agree to our Terms of Service and Privacy Policy; and, you acknowledge that your information may be shared with the content publisher.
Alum is obtained as a bulk, raw material and must be compounded in a sterile setting into a finish pharmaceutical. This presents a large challenge for hospital pharmacies, since it involves nonsterile to sterile compounding. Edge Pharma developed a solution that eliminates this issue, making compounding of this medication straight-forward and low risk. Edge has the ability to apply this technique to other medications as well.
Similar content you might be interested in
